51 related articles for article (PubMed ID: 12568913)
1. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
[TBL] [Abstract][Full Text] [Related]
3. The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats.
Zamarripa CA; Pareek T; Schrock HM; Prisinzano TE; Blough BE; Sufka KJ; Freeman KB
Psychopharmacology (Berl); 2021 Dec; 238(12):3463-3476. PubMed ID: 34430992
[TBL] [Abstract][Full Text] [Related]
4. Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys.
Huskinson SL; Platt DM; Brasfield M; Follett ME; Prisinzano TE; Blough BE; Freeman KB
Psychopharmacology (Berl); 2020 Jul; 237(7):2075-2087. PubMed ID: 32372348
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
Zheng Y; Obeng S; Reinecke BA; Chen C; Phansalkar PS; Walentiny DM; Gerk PM; Liu-Chen LY; Selley DE; Beardsley PM; Zhang Y
Eur J Pharmacol; 2019 Dec; 865():172812. PubMed ID: 31743739
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
[TBL] [Abstract][Full Text] [Related]
7. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
8. Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats.
Henderson-Redmond A; Czachowski C
Psychopharmacology (Berl); 2014 Nov; 231(22):4309-21. PubMed ID: 24770627
[TBL] [Abstract][Full Text] [Related]
9. GPCR dimerization in brainstem nuclei contributes to the development of hypertension.
Sun GC; Ho WY; Chen BR; Cheng PW; Cheng WH; Hsu MC; Yeh TC; Hsiao M; Lu PJ; Tseng CJ
Br J Pharmacol; 2015 May; 172(10):2507-18. PubMed ID: 25573074
[TBL] [Abstract][Full Text] [Related]
10. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Beletskaya IO; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5625-9. PubMed ID: 21788135
[TBL] [Abstract][Full Text] [Related]
11. Expression and pharmacological modulation of visceral pain-induced conditioned place aversion in mice.
Bagdas D; Muldoon PP; AlSharari S; Carroll FI; Negus SS; Damaj MI
Neuropharmacology; 2016 Mar; 102():236-43. PubMed ID: 26639043
[TBL] [Abstract][Full Text] [Related]
12. Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.
Cornelissen JC; Obeng S; Rice KC; Zhang Y; Negus SS; Banks ML
J Pharmacol Exp Ther; 2018 Apr; 365(1):37-47. PubMed ID: 29330156
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.
Obeng S; Yuan Y; Jali A; Selley DE; Zhang Y
Eur J Pharmacol; 2018 May; 827():32-40. PubMed ID: 29530590
[TBL] [Abstract][Full Text] [Related]
14. Effects of sex and hydration status on kappa opioid receptor-mediated diuresis in rats.
Lalji HM; Bailey CP; Husbands SM; Bailey SJ
Basic Clin Pharmacol Toxicol; 2024 Jun; 134(6):792-804. PubMed ID: 38584299
[TBL] [Abstract][Full Text] [Related]
15. Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice.
Spetea M; Eans SO; Ganno ML; Lantero A; Mairegger M; Toll L; Schmidhammer H; McLaughlin JP
Br J Pharmacol; 2017 Aug; 174(15):2444-2456. PubMed ID: 28494108
[TBL] [Abstract][Full Text] [Related]
16. Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.
Yuan Y; Elbegdorj O; Beletskaya IO; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2013 Sep; 23(18):5045-8. PubMed ID: 23948248
[TBL] [Abstract][Full Text] [Related]
17. Analgesia induced by localized injection of opiate peptides into the brain of infant rats.
Barr GA; Wang S
Eur J Pain; 2013 May; 17(5):676-91. PubMed ID: 23203254
[TBL] [Abstract][Full Text] [Related]
18. Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy.
Schrader TO; Lorrain KI; Bagnol D; Edu GC; Broadhead A; Baccei C; Poon MM; Stebbins KJ; Xiong Y; Lorenzana AO; Chan JR; Green AJ; Lorrain DS; Chen A
ACS Chem Neurosci; 2024 Feb; 15(3):685-698. PubMed ID: 38265210
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists.
Pagare PP; Li M; Zheng Y; Kulkarni AS; Obeng S; Huang B; Ruiz C; Gillespie JC; Mendez RE; Stevens DL; Poklis JL; Halquist MS; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2022 Mar; 65(6):5095-5112. PubMed ID: 35255685
[TBL] [Abstract][Full Text] [Related]
20. Recent Chemical and Pharmacological Developments on 14-Oxygenated-
Spetea M; Schmidhammer H
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
